ATE446106T1 - Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier - Google Patents

Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier

Info

Publication number
ATE446106T1
ATE446106T1 AT02803755T AT02803755T ATE446106T1 AT E446106 T1 ATE446106 T1 AT E446106T1 AT 02803755 T AT02803755 T AT 02803755T AT 02803755 T AT02803755 T AT 02803755T AT E446106 T1 ATE446106 T1 AT E446106T1
Authority
AT
Austria
Prior art keywords
animal
human
immune response
pharmaceutical composition
triggering
Prior art date
Application number
AT02803755T
Other languages
English (en)
Inventor
Alexei Kirkin
Karine Djandjougazian
Jesper Zeuthen
Original Assignee
Dandrit Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dandrit Biotech As filed Critical Dandrit Biotech As
Application granted granted Critical
Publication of ATE446106T1 publication Critical patent/ATE446106T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02803755T 2001-11-29 2002-11-29 Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier ATE446106T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101770 2001-11-29
US33670601P 2001-12-07 2001-12-07
PCT/DK2002/000802 WO2003045427A2 (en) 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal

Publications (1)

Publication Number Publication Date
ATE446106T1 true ATE446106T1 (de) 2009-11-15

Family

ID=26069102

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02803755T ATE446106T1 (de) 2001-11-29 2002-11-29 Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier

Country Status (11)

Country Link
US (2) US7771998B2 (de)
EP (1) EP1448229B1 (de)
JP (1) JP2005515192A (de)
AT (1) ATE446106T1 (de)
AU (1) AU2002365291B2 (de)
DE (1) DE60234115D1 (de)
DK (1) DK1448229T3 (de)
ES (1) ES2335396T3 (de)
IL (1) IL161832A0 (de)
RU (1) RU2313365C2 (de)
WO (1) WO2003045427A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
ES2294346T3 (es) * 2002-11-28 2008-04-01 Peter Kufer Rt-pcr en tiempo real novedosa para la deteccion sensible de multiples transcripciones del gen mage.
DE602005027407D1 (de) * 2004-11-18 2011-05-19 Univ Hiroshima Nat Univ Corp Verfahren und Kit zur Proteinexpression und Regelung der Expression wiederholter Sequenzen, die durch Genamplifikation und -transformierung gebildet werden
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US8207300B2 (en) 2006-01-30 2012-06-26 Ludwig Institute For Cancer Research Ltd. CTSP cancer-testis antigens
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
KR101506751B1 (ko) * 2007-05-17 2015-03-27 디나벡크 가부시키가이샤 수상세포의 제조방법
JP2011529080A (ja) * 2008-07-24 2011-12-01 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 癌幹細胞を標的とする治療法
BRPI0920679A2 (pt) * 2008-10-08 2022-05-17 Intrexon Corp Células construídas expressando múltiplos imunomoduladores e usos das mesmas
EP3101122B1 (de) 2009-08-24 2023-06-14 Baylor College of Medicine Erzeugung von ctl-linien mit spezifizität gegen mehrere tumorantigene oder mehrere viren
AU2011232435B2 (en) * 2010-03-23 2016-01-28 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
GB201013443D0 (en) * 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
CN103945902B (zh) 2011-08-30 2018-07-20 阿斯泰克斯制药公司 地西他滨衍生物制剂
WO2013059784A1 (en) * 2011-10-20 2013-04-25 California Stem Cell, Inc. Antigen presenting cancer vaccine
JP5871228B2 (ja) * 2011-10-31 2016-03-01 国立大学法人佐賀大学 慢性副鼻腔炎の検出方法
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PL3591047T3 (pl) 2012-02-09 2022-12-05 Baylor College Of Medicine Mieszanki peptydowe do wytwarzania wielowirusowych ctl o szerokiej swoistości
WO2014007669A1 (ru) * 2012-07-04 2014-01-09 Volgushev Sergei Anatolievich Аутологичная клеточная вакцина для лечения онкологических заболеваний и способ ее получения
EP3316685A4 (de) 2015-07-02 2019-03-13 Otsuka Pharmaceutical Co., Ltd. Lyophilisierte pharmazeutische zusammensetzungen
EP3350600A4 (de) 2015-09-18 2019-04-17 Baylor College of Medicine Unterscheidung eines immunogenen antigens von einem pathogen und korrelation mit klinischer wirksamkeit
GB201520542D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN111182908A (zh) 2017-08-03 2020-05-19 大塚制药株式会社 药物化合物及其纯化方法
MX2021000421A (es) 2018-07-15 2021-05-12 Enochian Biopharma Inc Métodos y composiciones que usan células dendríticas recombinantes para el tratamiento del cáncer.
EP3903811A1 (de) 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Pharmazeutische zusammensetzung und verfahren zur induzierung einer immunantwort
CA3119597C (en) 2020-10-12 2023-07-11 R.G.C.C. Holdings AG Sars-cov-2 vaccines
EP3981425A1 (de) 2020-10-12 2022-04-13 R.G.C.C. Holdings AG Sars-cov-2-impfstoffe

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US20040241176A1 (en) 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
EP2149381A3 (de) * 2001-03-09 2010-05-05 Baylor Research Institute Verfahren zur Behandlung von Malignitäten durch Induktion von Blutimmunantworten

Also Published As

Publication number Publication date
WO2003045427A3 (en) 2004-03-25
US20060051324A1 (en) 2006-03-09
AU2002365291A1 (en) 2003-06-10
ES2335396T3 (es) 2010-03-26
US7771998B2 (en) 2010-08-10
DK1448229T3 (da) 2010-03-08
AU2002365291B2 (en) 2007-11-01
EP1448229A2 (de) 2004-08-25
EP1448229B1 (de) 2009-10-21
HK1086750A1 (zh) 2006-09-29
JP2005515192A (ja) 2005-05-26
US7723107B2 (en) 2010-05-25
IL161832A0 (en) 2005-11-20
US20090029457A1 (en) 2009-01-29
WO2003045427A2 (en) 2003-06-05
DE60234115D1 (de) 2009-12-03
RU2004119548A (ru) 2005-03-27
RU2313365C2 (ru) 2007-12-27

Similar Documents

Publication Publication Date Title
ATE446106T1 (de) Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
Baldwin et al. Rapid changes in tree leaf chemistry induced by damage: evidence for communication between plants
TR199800607T1 (xx) Dendritik h�cre uyar�c� fakt�r�.
ES2184769T3 (es) Metodos y composiciones para microencapsulacion de antigenos para utilizar como vacunas.
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
DE69033700D1 (de) Il-11 aus säugetier
NZ306653A (en) Isolated dna il-17 receptors
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ES2093778T3 (es) Nuevos anticuerpos y metodos para su uso.
ATA191889A (de) Fettsäurezusammensetzung, verfahren zu ihrer herstellung, ihre verwendung und pharmazeutische zusammensetzung, die sie enthält
BR9712971A (pt) Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
Liu et al. Malaria infection alters the expression of B‐cell activating factor resulting in diminished memory antibody responses and survival
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
Liang et al. Roles of the adenosine receptor and CD73 in the regulatory effect of γδ T cells
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
ES2165232T3 (es) Sistema terapeutico transdermico (tts) que contiene oxibutinina.
WO2001068697A3 (en) Methods and compositions for immunoregulation
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
Moughal et al. Langerhans cell dynamics in human gingiva during experimentally induced inflammation
Aukrust et al. Mold allergy-spores and mycelium as allergen sources.
DE69929432D1 (de) Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties